Singapore’s experience on integrated HPV vaccine delivery

Singapore’s HPV vaccination program integrates school-based delivery for 13-year-old girls and community-based services for women aged 18–26. Initially challenged by low awareness and uptake, interventions included adding HPV vaccines to the national schedule, subsidizing costs through CHAS clinics, and implementing targeted outreach such as letters and SMS reminders to encourage appointments. A life-course approach links […]

Country experiences on delivery strategies; Myanmar EPI

Myanmar introduced HPV vaccination in 2020 targeting 9-year-old girls but faced program interruptions in 2021–2022 due to instability and supply shortages. In 2023, the program resumed with a catch-up campaign, shifting from a two-dose to a single-dose schedule aligned with WHO recommendations. Delivery combined school-based and community approaches, supported by the Vaccine Management Information System […]

Country experiences on delivery strategies; Malaysia

Malaysia introduced HPV vaccination in 2010 for 13‑year‑old girls as a cancer prevention strategy, later expanding to catch‑up cohorts. The program, delivered mainly through school health services, achieved high coverage due to strong Ministry of Education collaboration, parental trust, and integration into the National Immunization Program. Policy shifts moved from three‑ to single‑dose schedules and […]

Malaysia: Partnership with CSOs for HPV vaccine coverage recovery

The National Cancer Society Malaysia (NCSM) leads HPV vaccine coverage recovery through public-private-NGO collaboration, addressing disruptions caused by COVID-19. Their “Leaving No One Behind” program targets underserved groups, including rural populations, refugees, and out-of-school youth. Implementation combines health education, localized outreach, and strong community partnerships to combat hesitancy and improve access. Future plans include expanding […]

Single-dose scientific evidence data and implementation progress

The session reviewed global evidence underpinning the WHO’s 2022 recommendation for single-dose HPV vaccination. Data from pivotal trials in Costa Rica, India, and Kenya demonstrated sustained efficacy exceeding 80–90% against HPV 16/18 infection for over a decade. Immunogenicity studies confirmed durable antibody responses comparable to multi-dose schedules, with similar outcomes in boys and girls. Population-level […]

Decision-making to switch to single dose

The presentation outlines Myanmar’s policy shift from a two-dose to a single-dose HPV vaccination schedule, driven by operational challenges during COVID-19, missed cohorts, and WHO’s updated recommendations. NITAG adopted a systematic, evidence-based approach using PICO criteria to guide decision-making, ensuring transparency and technical rigor. The revised strategy targets 9–11-year-old girls through school and community campaigns, […]

>